Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Koopman LA, Alemdehy F, de Poot SAH, Paauwe M, Wang W, Epstein KR, van den Brink EN, Gorlani A, Verzijl D, Brandhorst M, Franken P, Smits-de Vries L, Gielen E, Plantinga TS, Houtkamp M, Engelberts PJ, Lihme Egerod F, Thalhauser CJ, Bosgra S, Gitto SB, Powell DJ, Gamse JT, Overdijk MB, Breij ECW.

Open source

DOI: 10.1158/1535-7163.mct-26-0054
Published: 2026-06-30
Container: Mol Cancer Ther
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1535-7163.mct-26-0054,
  title = {Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.},
  author = {Koopman LA and  Alemdehy F and  de Poot SAH and  Paauwe M and  Wang W and  Epstein KR and  van den Brink EN and  Gorlani A and  Verzijl D and  Brandhorst M and  Franken P and  Smits-de Vries L and  Gielen E and  Plantinga TS and  Houtkamp M and  Engelberts PJ and  Lihme Egerod F and  Thalhauser CJ and  Bosgra S and  Gitto SB and  Powell DJ and  Gamse JT and  Overdijk MB and  Breij ECW.},
  year = {2026},
  journal = {Mol Cancer Ther},
  doi = {10.1158/1535-7163.mct-26-0054},
  url = {https://doi.org/10.1158/1535-7163.mct-26-0054}
}

RIS

TY  - JOUR
TI  - Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.
AU  - Koopman LA
AU  -  Alemdehy F
AU  -  de Poot SAH
AU  -  Paauwe M
AU  -  Wang W
AU  -  Epstein KR
AU  -  van den Brink EN
AU  -  Gorlani A
AU  -  Verzijl D
AU  -  Brandhorst M
AU  -  Franken P
AU  -  Smits-de Vries L
AU  -  Gielen E
AU  -  Plantinga TS
AU  -  Houtkamp M
AU  -  Engelberts PJ
AU  -  Lihme Egerod F
AU  -  Thalhauser CJ
AU  -  Bosgra S
AU  -  Gitto SB
AU  -  Powell DJ
AU  -  Gamse JT
AU  -  Overdijk MB
AU  -  Breij ECW.
PY  - 2026
JO  - Mol Cancer Ther
DO  - 10.1158/1535-7163.mct-26-0054
UR  - https://doi.org/10.1158/1535-7163.mct-26-0054
ER  -

APA

LA, K., F, A., SAH, D. P., M, P., W, W., KR, E., EN, V. D. B., A, G., D, V., M, B., P, F., L, S. V., E, G., TS, P., M, H., PJ, E., F, L. E., CJ, T., S, B., SB, G., DJ, P., JT, G., MB, O., & ECW., B. (2026). Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.mct-26-0054

Source records

europe-pmc · retrieved 2026-09-27T06:22:46.701Z